Glimpse the Future in Synthetic Biology, Cancer and Stem Cells at MASS Opportunities with Leading Researchers Drew Endy, Tyler Jacks and Leonard Zon.Harvard's Isaac Kohlberg, Comerica's Janice Bourque, Healthcare Ventures Chris Mirabelli, other experts to address early-stage biotech funding challenges CAMBRIDGE, Mass. -- Opportunities on the horizon in synthetic biology, cancer and stem cell research and meeting the challenge of early-stage financing in biotechnology are among the featured sessions at the Massachusetts Biotechnology Council's (MBC (Multimedia Benchmark Committee) A graphics benchmark that provides MPEG-2 and other tests. See GPC. ) annual investor conference and partnering forum. MASSOpportunities, New England's largest biotechnology investor forum, will take place on November 2 at the Hilton Boston Logan Airport, Boston, MA. "Pioneering academic research and the willingness of investors to support the next generation of innovations have combined to make Massachusetts a world center of biotechnology," stated MBC President Thomas Finneran. "These compelling sessions will highlight some of the most promising areas that will generate new enterprises and explore new ways to support early-stage ventures." Opportunities on the Horizon, chaired by Jeffrey Wiesen, Partner & Chairman, Biotechnology Practice of Mintz Levin, will provide a forum for scientific and venture leaders to share their thoughts on where the future lies with synthetic biology, cancer, and stem cell research. The roundtable participants include: * Drew Endy, Ph.D., Assistant Professor, Biological Engineering, MIT MIT - Massachusetts Institute of Technology * Jonathan Fleming, Managing General Partner, Oxford Bioscience Partners * Tyler Jacks, Ph.D., David H. Koch David Hamilton Koch (born 1940) is one of the billionaire co-owners (with older brother Charles) and an executive vice president of Koch Industries, a conglomerate with major oil and gas holdings that is the largest privately held company in the United States. Professor of Biology & Director, Center for Cancer Research, MIT * Leonard Zon, M.D., Grousbeck Professor Hematology/Oncology & Director, Stem Cell Research Program, Children's Hospital Boston Children's Hospital Boston is a children's hospital located in the Longwood Medical and Academic Area of Boston, Massachusetts. Located at 300 Longwood Avenue, Children's is adjacent both to its teaching affiliate, Harvard Medical School, and to Dana-Farber Cancer Institute. and Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. The meeting's second roundtable, Funding Conundrum: Investing in Early-Stage Technologies, will survey the biotechnology industry's funding landscape and outline new approaches for financing biomedical innovations. The roundtable, co-chaired by William Asher, Partner, Choate, Hall & Stewart LLP LLP - Lower Layer Protocol and Janice Bourque, Sr. Vice President & Group Head-Life Sciences, Comerica Bank, will feature commercial, academic and venture capital speakers, including: * Isaac Kohlberg, Chief Technology Development Officer, Harvard University Office of Technology Development * Chris Mirabelli, Ph.D., Managing Director, Healthcare Ventures LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control * Maggie Flanagan, Ph.D., Global Alliance Director, Global Sciences and Information, AstraZeneca * Donald P. Lombardi, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Institute for Pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. Innovation The MASSOpportunities Annual Conference is open to members of the biotechnology industry, and members of the press and financial communities. To register, or for more information, visit the MBC's website at: www.massopps.com, or contact the MBC at (617) 674-5100. About the MBC The Massachusetts Biotechnology Council (MBC), founded in 1985, is a non-profit organization that provides services and support for the Massachusetts biotechnology industry. The MBC is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 500 companies, academic institutions and service organizations involved in biotechnology and healthcare, the MBC works with public leaders to advance policy and promote education, while providing member programs and services. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion